Literature DB >> 12511416

Acceleration of idiopathic pneumonia syndrome (IPS) in the absence of donor MIP-1 alpha (CCL3) after allogeneic BMT in mice.

Angela Panoskaltsis-Mortari1, John R Hermanson, Elizabeth Taras, O Douglas Wangensteen, Jonathan S Serody, Bruce R Blazar.   

Abstract

Idiopathic pneumonia syndrome (IPS) is a significant cause of morbidity and mortality after bone marrow transplantation (BMT) in humans. We developed a murine IPS model in which lethal pre-BMT conditioning and allogeneic T cells results in the recruitment of host monocytes and then donor T cells into the lung by day 7 after BMT, concomitant with development of severe lung dysfunction. We reported the T cell-dependent production of the T cell-attracting chemokine macrophage inflammatory protein-1 alpha (MIP-1 alpha) in the lungs of such recipient mice. We reasoned that MIP-1 alpha might be a critical mediator of IPS. Lethally conditioned mice received transplants of major histocompatibility complex-disparate marrow and either wild-type (MIP-1 alpha(+/+)) or knockout (MIP-1 alpha(-/-)) spleen cells. Recipients of MIP-1 alpha(-/-) cells exhibited accelerated mortality and a decrease in specific compliance that appeared earlier than in recipients of MIP-1 alpha(+/+) cells. Donor CD4(+) and CD8(+) T cell expansion was increased in the spleens of recipients of MIP-1 alpha(-/-) cells. Lungs of recipients of MIP-1 alpha(-/-) cells had earlier recruitment of both T-cell subsets by day 3 after BMT, concomitant with the influx of cells expressing the cytolysins granzymes A and B. Monocyte recruitment was not altered. Levels of inflammatory cytokines were not increased and levels of T cell-attracting chemokines were decreased. The level of the anti-inflammatory cytokine interleukin 13 (IL-13) was lower in the serum and lungs of recipients of MIP-1 alpha(-/-) cells, indicating a skewing toward a more inflammatory T helper cell type 1 (Th1) cytokine milieu. Donor-derived MIP-1 alpha may play a role in allogeneic-induced IPS by limiting aggressive expansion of CD4(+) and CD8(+) T cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12511416     DOI: 10.1182/blood-2002-08-2465

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

Review 1.  An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome.

Authors:  Angela Panoskaltsis-Mortari; Matthias Griese; David K Madtes; John A Belperio; Imad Y Haddad; Rodney J Folz; Kenneth R Cooke
Journal:  Am J Respir Crit Care Med       Date:  2011-05-01       Impact factor: 21.405

2.  Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease.

Authors:  Christian A Wysocki; Qi Jiang; Angela Panoskaltsis-Mortari; Patricia A Taylor; Karen P McKinnon; Lishan Su; Bruce R Blazar; Jonathan S Serody
Journal:  Blood       Date:  2005-07-07       Impact factor: 22.113

Review 3.  Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD).

Authors:  Bruce R Blazar; William J Murphy
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

4.  Chemokine receptor CCR5 mediates alloimmune responses in graft-versus-host disease.

Authors:  Lisa A Palmer; George E Sale; John I Balogun; Dan Li; Dan Jones; Jeffrey J Molldrem; Rainer F Storb; Qing Ma
Journal:  Biol Blood Marrow Transplant       Date:  2009-12-16       Impact factor: 5.742

5.  Targeting the Canonical Nuclear Factor-κB Pathway with a High-Potency IKK2 Inhibitor Improves Outcomes in a Mouse Model of Idiopathic Pneumonia Syndrome.

Authors:  Kenneth A Fowler; Corey M Jania; Stephen L Tilley; Angela Panoskaltsis-Mortari; Albert S Baldwin; Jonathan S Serody; James M Coghill
Journal:  Biol Blood Marrow Transplant       Date:  2017-02-01       Impact factor: 5.742

Review 6.  Leukocyte migration and graft-versus-host disease.

Authors:  Christian A Wysocki; Angela Panoskaltsis-Mortari; Bruce R Blazar; Jonathan S Serody
Journal:  Blood       Date:  2005-02-08       Impact factor: 22.113

7.  Preventive usage of broad spectrum chemokine inhibitor NR58-3.14.3 reduces the severity of pulmonary and hepatic graft-versus-host disease.

Authors:  Sandra Miklos; Gunnar Mueller; Yayi Chang; Abdellatif Bouazzaoui; Elena Spacenko; Thomas E O Schubert; David J Grainger; Ernst Holler; Reinhard Andreesen; Gerhard C Hildebrandt
Journal:  Int J Hematol       Date:  2009-03-14       Impact factor: 2.490

8.  Altered levels of CC chemokines during pulmonary CMV predict BOS and mortality post-lung transplantation.

Authors:  S S Weigt; R M Elashoff; M P Keane; R M Strieter; B N Gomperts; Y Y Xue; A Ardehali; A L Gregson; B Kubak; M C Fishbein; R Saggar; D J Ross; J P Lynch; D A Zisman; J A Belperio
Journal:  Am J Transplant       Date:  2008-07       Impact factor: 8.086

Review 9.  Immunomodulation and pharmacological strategies in the treatment of graft-versus-host disease.

Authors:  Minghui Li; Kai Sun; Lisbeth A Welniak; William J Murphy
Journal:  Expert Opin Pharmacother       Date:  2008-09       Impact factor: 3.889

10.  Long-Lasting Graft-Derived Donor T Cells Contribute to the Pathogenesis of Chronic Graft-versus-Host Disease in Mice.

Authors:  Mizuha Kosugi-Kanaya; Satoshi Ueha; Jun Abe; Shigeyuki Shichino; Francis H W Shand; Teppei Morikawa; Makoto Kurachi; Yusuke Shono; Naoto Sudo; Ai Yamashita; Fumiko Suenaga; Akihiro Yokoyama; Wang Yong; Masahiro Imamura; Takanori Teshima; Kouji Matsushima
Journal:  Front Immunol       Date:  2017-12-18       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.